Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2009;189:155–176. doi: 10.1007/978-3-540-79086-0_6

Other Inhibitors of Viral Enzymes and Functions

H Zimmermann 2,✉, G Hewlett 3,✉, H Rübsamen-Waigmann 2
Editors: Hans-Georg Kräusslich*, Ralf Bartenschlager*
PMCID: PMC7122372  PMID: 19048200

Abstract

Until the end of the 1970s, the mainstays of antiviral chemotherapy were nucleoside analogues that targeted virus polymerase, in particular, the herpesvirus DNA polymerase. The scourge of HIV triggered an unprecedented commitment to identify novel antivirals, and these efforts transformed antiviral therapy into the modern, sophisticated treatment form described in this book, with targets such as the reverse transcriptase and the protease as well as the entry of the human immunodeficiency virus. As the regulation of human pathogenic virus growth cycles became more understandable, the realisation grew that these pathogens had more than one Achilles heel that might be suitable targets for small molecules with antiviral activity. This chapter addresses those “other” targets as well as other approaches to the tried and tested polymerase inhibitors, the so-called non-nucleoside inhibitors of reverse transcriptase.

Keywords: Herpes Simplex Virus Type, Severe Acute Respiratory Syndrome, Human Cytomegalovirus, Severe Acute Respiratory Syndrome, Integrase Inhibitor

Contributor Information

Hans-Georg Kräusslich, Email: hans-georg_kraeusslich@med.uni-heidelberg.de.

Ralf Bartenschlager, Email: ralf_bartenschlager@med.uni-heidelberg.de.

H. Zimmermann, Email: holger.zimmermann@aicuris.com

G. Hewlett, Email: hbsc@arcor.de

H. Rübsamen-Waigmann, Email: helga.ruebsamen-waigmann@aicuris.com

References

  1. Al-Kobaisi MF, Rixon FJ, McDougall I, Preston VG. The herpes simplex virus UL33 gene product is required for the assembly of full capsids. Virology. 1991;180:380–388. doi: 10.1016/0042-6822(91)90043-B. [DOI] [PubMed] [Google Scholar]
  2. Anthony NJ. HIV-1 integrase: a target for new AIDS chemotherapeutics. Curr Top Med Chem. 2004;4:979–990. doi: 10.2174/1568026043388448. [DOI] [PubMed] [Google Scholar]
  3. Arvin AM, Alford CA. Chronic intrauterine and perinatal infections. In: Galasso GJ, Whitley RJ, Merigan TC, editors. Antiviral agents and viral diseases of man. 3. NY: Raven; 1990. pp. 497–580. [Google Scholar]
  4. Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res. 1999;52:351–369. doi: 10.1016/S0065-3527(08)60306-1. [DOI] [PubMed] [Google Scholar]
  5. Azad RF, Driver VB, Tanaka K, Crooke RM, Anderson KP. Antiviral activity of a phos-phorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother. 1993;37:1945–1954. doi: 10.1128/aac.37.9.1945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bacheler LS, Jeffrey GH, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75:4999–5008. doi: 10.1128/JVI.75.11.4999-5008.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Baines JD, Cunningham C, Nalwanga D, Davison A. The UL15 gene of herpes simplex virus type 1 contains within its second exon a novel open reading frame that is translated in frame with the UL15 gene product. J Virol. 1997;71:2666–2673. doi: 10.1128/jvi.71.4.2666-2673.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem. 2004;4:921–944. doi: 10.2174/1568026043388420. [DOI] [PubMed] [Google Scholar]
  9. Baumeister J, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G. Superior efficacy of helicase-primase inhibitor BAY 57–1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir Chem Chemother. 2007;18:35–48. doi: 10.1177/095632020701800104. [DOI] [PubMed] [Google Scholar]
  10. Beard PM, Duffy C, Baines JD. Quantification of the DNA cleavage and packaging proteins UL15 and UL28 in A and B capsids of herpes simplex virus type 1. J Virol. 2004;78:1367–1374. doi: 10.1128/JVI.78.3.1367-1374.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Betz UA, Fischer R, Kleymann G, Hendrix M, Rubsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57–1293. Antimi-crob Agents Chemother. 2002;46:1766–1772. doi: 10.1128/AAC.46.6.1766-1772.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bhattacharyya SP, Rao VB. A novel terminase activity associated with the DNA packaging protein gp17 of bacteriophage T4. Virology. 1993;196:34–44. doi: 10.1006/viro.1993.1452. [DOI] [PubMed] [Google Scholar]
  13. Bhattacharyya SP, Rao VB. Structural analysis of DNA cleaved in vivo by bacteriophage T4 terminase. Gene. 1994;146:67–72. doi: 10.1016/0378-1119(94)90834-6. [DOI] [PubMed] [Google Scholar]
  14. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs. 2003;4:206–209. [PubMed] [Google Scholar]
  15. Black LW. DNA packaging in dsDNA bacteriophages. In: Calendar R, editor. The bacterio-phages. NY: Plenum; 1988. pp. 321–373. [Google Scholar]
  16. Bogner E. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev Med Virol. 2002;12:115–127. doi: 10.1002/rmv.344. [DOI] [PubMed] [Google Scholar]
  17. Bogner E, Reschke M, Reis B, Mockenhaupt T, Radsak K. Identification of the gene product encoded by ORF UL56 of the human cytomegalovirus genome. Virology. 1993;196:290–293. doi: 10.1006/viro.1993.1477. [DOI] [PubMed] [Google Scholar]
  18. Bogner E, Radsak K, Stinski MF. The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J Virol. 1998;72:2259–2264. doi: 10.1128/jvi.72.3.2259-2264.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Borowski P, Deinert J, Schalinski S, et al. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur J Biochem. 2003;270:1645–1653. doi: 10.1046/j.1432-1033.2003.03540.x. [DOI] [PubMed] [Google Scholar]
  20. Bürger I, Reefschläger J, Bender W, Eckenberg P, Popp A, Weber O, Graeper S, Klenk HD, Rübsamen-Waigmann H, Hallenberger S. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol. 2001;75:9077–9086. doi: 10.1128/JVI.75.19.9077-9086.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Casado JL, Perez-Elias MJ, Marti-Belda P, Antela A, Suarez M, Ciancas E. Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:130–134. doi: 10.1097/00042560-199810010-00005. [DOI] [PubMed] [Google Scholar]
  22. Catalano CE. The terminase enzyme from bacteriophage lambda: a DNA-packaging machine. Cell Mol Life Sci. 2000;57:128–148. doi: 10.1007/s000180050503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Chee MS, Bankeir AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnel T, Hutchinson CAI, Kouzarides T, Martignetti JA, Preddie E, Satchwell SP, Tomlinson P, Weston KM, Barrel BG. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol. 1990;154:125–170. doi: 10.1007/978-3-642-74980-3_6. [DOI] [PubMed] [Google Scholar]
  24. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem. 2004;4:965–977. doi: 10.2174/1568026043388547. [DOI] [PubMed] [Google Scholar]
  25. Chulay J, Biron K, Want L, Underwood M, Chamberlain S, Frick L, Good S, Davis M, Harvey R, Townsend L, Drach J, Koszalka G. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. In: Mills J, Volberding P, Corey L, editors. Antiviral therapy 5: new directions for clinical applications and research. NY: Kluwer/Plenum; 1999. pp. 129–134. [DOI] [PubMed] [Google Scholar]
  26. Cobb JA, Bjergbaek L. RecQ helicases: lessons from model organisms. Nucleic Acids Res. 2006;34:4106–4114. doi: 10.1093/nar/gkl557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Crute JJ, Grygon CA, Hargrave KD, Simoneau B, Faucher AM, Bolger G, Kibler P, Liuzzi M, Cordingley MG. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med. 2002;8:386–391. doi: 10.1038/nm0402-386. [DOI] [PubMed] [Google Scholar]
  28. De Clercq E. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med Res Rev. 1993;13:229–258. doi: 10.1002/med.2610130303. [DOI] [PubMed] [Google Scholar]
  29. de Jong MD, Galasso GJ, Gazzard B, Griffiths PD, Jabs DA, Kern ER, et al. Summary of the II international symposium on cytomegalovirus. Antiviral Res. 1998;39:141–162. doi: 10.1016/S0166-3542(98)00044-8. [DOI] [PubMed] [Google Scholar]
  30. Debyser Z, Cherepanov P, Van Maele B, De Clercq E, Witvrouw M. In search of authentic inhibitors of HIV-1 integration. Antivir Chem Chemother. 2002;13:1–15. doi: 10.1177/095632020201300101. [DOI] [PubMed] [Google Scholar]
  31. Deeks SG. International perspectives on antiretroviral resistance. Non-nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001;26:25–33. doi: 10.1097/00042560-200103011-00004. [DOI] [PubMed] [Google Scholar]
  32. Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 2003;299:893–896. doi: 10.1126/science.1077215. [DOI] [PubMed] [Google Scholar]
  33. Drew W, Paya C, Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant. 2001;1:307–312. [PubMed] [Google Scholar]
  34. Embrey MW, Wai JS, Funk TW, Homnick CF, Perlow DS, Young SD, Vacca JP, Hazuda DJ, Felock PJ, Stillmock KA, Witmer MV, Moyer G, Schleif WA, Gabryelski LJ, Jin L, Chen I, Ellis JD, Wong BK, Lin JH, Leonard YM, Tsou NN, Zhuang L. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett. 2005;15:4550–4554. doi: 10.1016/j.bmcl.2005.06.105. [DOI] [PubMed] [Google Scholar]
  35. Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, Egbertson M, Melamed JY, Young S, Hamill T, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA. 2000;97:11244–11249. doi: 10.1073/pnas.200139397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Esposito D, Craigie R. HIV integrase structure and function. Adv Virus Res. 1999;52:319–333. doi: 10.1016/S0065-3527(08)60304-8. [DOI] [PubMed] [Google Scholar]
  37. Evering TH, Markowitz M. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today (Barc) 2007;43:865–877. doi: 10.1358/dot.2007.43.12.1146063. [DOI] [PubMed] [Google Scholar]
  38. Falagas ME, Paya C, Ruthazer R, Badley A, Patel R, Wiesner R, et al. Significance of cy-tomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation. 1998;66:1020–1028. doi: 10.1097/00007890-199810270-00010. [DOI] [PubMed] [Google Scholar]
  39. Field AK. Human cytomegalovirus: challenges, opportunities and new drug development. Antivir Chem Chemother. 1999;10:219–232. doi: 10.1177/095632029901000501. [DOI] [PubMed] [Google Scholar]
  40. Frick DN. Helicases as antiviral drug targets. Drug News Perspect. 2003;16:355–362. doi: 10.1358/dnp.2003.16.6.829307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Frick DN. Step-by-step progress toward understanding the hepatitis C virus RNA helicase. Hepatology. 2006;43:1392–1395. doi: 10.1002/hep.21200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Frick DN. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr Issues Mol Biol. 2007;9:1–20. [PMC free article] [PubMed] [Google Scholar]
  43. Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J, vant' Klooster GA. An open-label assessment of TMC 125 a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS. 2003;17:49–54. doi: 10.1097/00002030-200312050-00001. [DOI] [PubMed] [Google Scholar]
  44. Gibson W. Structure and assembly of the virion. Intervirology. 1996;39:389–400. doi: 10.1159/000150509. [DOI] [PubMed] [Google Scholar]
  45. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA. 1991;88:6863–6867. doi: 10.1073/pnas.88.15.6863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Gorbalenya AE, Koonin EV. Helicases: amino acid sequence comparisons and structure- function relationships. Curr Opin Struct Biol. 1993;3:419–429. doi: 10.1016/S0959-440X(05)80116-2. [DOI] [Google Scholar]
  47. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261–1269. doi: 10.1016/S0140-6736(07)60597-2. [DOI] [PubMed] [Google Scholar]
  48. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA. 2002;99:6661–6666. doi: 10.1073/pnas.092056199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Gruzdev B, Rakhmanova A, Doubovskaya E, Yakovlev A, Peeters M, Rinehart A, de Dier K, Baed-van Dijk B, Parys W, van't Klooster G. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral näive, HIV-1 infected subjects. AIDS. 2003;17:2487–2494. doi: 10.1097/00002030-200311210-00011. [DOI] [PubMed] [Google Scholar]
  50. Hammond JN, Leavitt MC, Rudy JJ, Isaacson JS, Hertogs K, Larder BA, Pattick AK (2003) Long-term virological response to capravirine in HIV-infected NNRTI-experienced patients. In: 43rd interscience conference on antimicrobial agents and chemotherapy. Chicago, IL, Abstract H-871
  51. Harada K, Eizuru Y, Isashiki Y, Ihara S, Minamishima Y. Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir. Arch Virol. 1997;142:215–225. doi: 10.1007/s007050050072. [DOI] [PubMed] [Google Scholar]
  52. Hazuda D, Schleif W, Gabryelski L, Grobler J, Felock P, Stillmock K, Espeseth A, Danzeisen R, Danovich R, Miller M, Witmer M. Resistance to integration inhibitors: evolution of active site mutations, relationship to fitness and enzyme co-factor utilization. Antivir Ther. 2001;6:4. [Google Scholar]
  53. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646–650. doi: 10.1126/science.287.5453.646. [DOI] [PubMed] [Google Scholar]
  54. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP Jr, Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen I-W, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK, Young SD. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA. 2004;101:11233–11238. doi: 10.1073/pnas.0402357101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Hepatitis C Support project, Hepatitis C Basics (2006) New HCV antivirals and drug resistance. http://www.hcvadvocate.org
  56. Herandez J, Amador L, Amantea M, Chao H, Hawley P, Paradiso L (2000) Short-course monother-apy with AG1549, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), in an-tiretroviral näive patients. In: 7th conference on retroviruses and opportunistic infections. San Francisco, CA, Abstract 669
  57. Hwang J-S, Bogner E. ATPase activity of the terminase subunit pUL56 of human cy-tomegalovirus. J Biol Chem. 2002;27:6943–6948. doi: 10.1074/jbc.M108984200. [DOI] [PubMed] [Google Scholar]
  58. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623–683. [PMC free article] [PubMed] [Google Scholar]
  59. Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis. 1998a;177:770–773. doi: 10.1086/514249. [DOI] [PubMed] [Google Scholar]
  60. Jabs DA, Enger C, Forman M, Dunn JP. Incidence of foscarnet resistance and cido-fovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob Agents Chemother. 1998b;42:2240–2244. doi: 10.1128/aac.42.9.2240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Kehlenbeck S, Betz U, Birkmann A, Fast B, Göller AH, Henninger K, Lowinger T, Marrero D, Paessens A, Paulsen D, Pevzner V, Schoh -Loop R, Tsujishita H, Welker R, Kreuter J, Rübsamen-Waigmann H, Dittmer F. Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore. J Virol. 2006;80:6883–6894. doi: 10.1128/JVI.00306-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Kesel AJ. Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS) Curr Med Chem. 2005;12:2095–2162. doi: 10.2174/0929867054637644. [DOI] [PubMed] [Google Scholar]
  63. Kleymann G, Fischer R, Betz UAK, Hendrix M, Bender W, Schneider U, Handke G, Eckenberg P, Hewlett G, Pevzner V. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med. 2002;8:392–398. doi: 10.1038/nm0402-392. [DOI] [PubMed] [Google Scholar]
  64. Kohlstaedt LA, Wang J, Fiedman JM, Rice PA, Steitz TA. A crystal structure at 3.5 Åresolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256:1783–1790. doi: 10.1126/science.1377403. [DOI] [PubMed] [Google Scholar]
  65. Krosky P, Underwood M, Turk S, Feng K, Jain R, Ptak R, Westerman A, Biron K, Townsend L, Drach J. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol. 1998;72:4721–4758. doi: 10.1128/jvi.72.6.4721-4728.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Lamberti C, Weller SK. The herpes simplex type 1 UL6 protein is essential for cleavage and packaging but not for genomic inversion. Virology. 1996;226:403–407. doi: 10.1006/viro.1996.0668. [DOI] [PubMed] [Google Scholar]
  67. Lamberti C, Weller SK. The herpes simplex virus type 1 cleavage/packaging protein, UL32, is involved in efficient localization of capsids to replication compartments. J Virol. 1998;72:2463–2473. doi: 10.1128/jvi.72.3.2463-2473.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1994–1997. JAMA. 2001;285:1308–1315. doi: 10.1001/jama.285.10.1308. [DOI] [PubMed] [Google Scholar]
  69. Li L, Olvera JM, Yoder KE, Mitchell RS, Butler SL, Lieber M, Martin SL, Bushman FD. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J. 2001;20:3272–3281. doi: 10.1093/emboj/20.12.3272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, Ruiz N, Brun S, Sun E, Perelson AS, Ho DD, Markowitz M. Determining the relative efficacy of highly active antiretro-viral therapy. J Infect Dis. 2003;187:896–900. doi: 10.1086/368164. [DOI] [PubMed] [Google Scholar]
  71. Maga G, Gemma S, Fattorusso C. Specific targeting of hepatitis virus C NS3 helicase. Biochemistry. 2005;44:9637–9644. doi: 10.1021/bi047437u. [DOI] [PubMed] [Google Scholar]
  72. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morale-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125–133. doi: 10.1097/QAI.0b013e318157131c. [DOI] [PubMed] [Google Scholar]
  73. McNab AR, Desai P, Person S, Roof LL, Thomsen DR, Newcomb WW, Brown JC, Homa FL. The product of the herpes simplex virus type 1 UL25 gene is required for encapsidation but not for cleavage of replicated viral DNA. J Virol. 1998;72:1060–1070. doi: 10.1128/jvi.72.2.1060-1070.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990;250:1411–1413. doi: 10.1126/science.1701568. [DOI] [PubMed] [Google Scholar]
  75. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H, Cooper DA. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007;21:2315–2321. doi: 10.1097/QAD.0b013e3282f12377. [DOI] [PubMed] [Google Scholar]
  76. Nagelschmitz J, Moeller JG, Stass HH, Wadel C, Kuhlmann J (1999) Safety, tolerability, and phar-macokinetics of single oral doses of BAY 38–4766—a novel nonnucleosidic inhibitor of human cytomegalovirus (HCMV) replication—in healthy male subjects. In: Interscience conference on antimicrobial agents and chemotherapy. American Society for Microbiology, WA, Abstract 945
  77. Patel AH, Rixon FJ, Cunningham C, Davison AJ. Isolation and characterization of herpes simplex virus type 1 mutants defective in the UL6 gene. Virology. 1996;217:111–123. doi: 10.1006/viro.1996.0098. [DOI] [PubMed] [Google Scholar]
  78. Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol. 2004;4:437–446. doi: 10.1016/j.coph.2004.07.005. [DOI] [PubMed] [Google Scholar]
  79. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 1990;343:470–474. doi: 10.1038/343470a0. [DOI] [PubMed] [Google Scholar]
  80. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, Dimitrov MA, Pizzo P, Yarchoan R, Dimitrov DS. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet. 2001;358:1760–1765. doi: 10.1016/S0140-6736(01)06802-7. [DOI] [PubMed] [Google Scholar]
  81. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005;4:236–248. doi: 10.1038/nrd1660. [DOI] [PubMed] [Google Scholar]
  82. Reefschlaeger J, Bender W, Eckenberg P, Goldmann S, Haerter M, Hallenberger S et al (1999) Antiviral activity and selectivity of BAY 38–4766—a novel nonnucleosidic inhibitor of human cytomegalovirus replication. In: Interscience conference on antimicrobial agents and chemotherapy. American Society for Microbiology, WA, Abstract 942
  83. Rübsamen-Waigmann H, Huguenel E, Paessens A, Kleim JP, Wainberg MA, Shah A. Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load. Lancet. 1997;349:1517. doi: 10.1016/S0140-6736(97)24021-3. [DOI] [PubMed] [Google Scholar]
  84. Sarasini A, Baldanti F, Furione M, Percivalle E, Brerra R, Barbi M. Double resistance to ganciclovir and foscarnet of 4 human cytomegalovirus strains recovered from AIDS patients. J Med Virol. 1995;47:237–244. doi: 10.1002/jmv.1890470309. [DOI] [PubMed] [Google Scholar]
  85. Satoh M, Motomura T, Matsuda T, Kondo K, Ando K, Matsuda K, Miyake S, Uehara H (2005) 4-Oxoquinoline compounds and utilization thereof as HIV integrase inhibitors. PCT Int. Appl. WO 2005113508
  86. Savva CGW, Holzenburg A, Bogner E. Insights into the structure of human cytomegalovirus large terminase subunit pUL56. FEBS Lett. 2004;563:135–140. doi: 10.1016/S0014-5793(04)00283-2. [DOI] [PubMed] [Google Scholar]
  87. Scheffczik H, Savva CGW, Holzenburg A, Kolesnikova L, Bogner E. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucleic Acids Res. 2002;30:1695–1703. doi: 10.1093/nar/30.7.1695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Scholz B, Rechter S, Drach JC, Townsend LB, Bogner E. Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Res. 2003;31:1426–1433. doi: 10.1093/nar/gkg229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA. 2008;105:4832–4837. doi: 10.1073/pnas.0711372105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Sheaffer AK, Newcomb WW, Gao M, Yu D, Weller SK, Brown JC, Tenney DJ. Herpes simplex virus DNA cleavage and packaging proteins associate with the procapsid prior to its maturation. J Virol. 2001;75:687–698. doi: 10.1128/JVI.75.2.687-698.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) J Virol. 2008;82:764–774. doi: 10.1128/JVI.01534-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. Genetic correlates of efavirenz hypersusceptibility. AIDS. 2004;13:1781–1785. doi: 10.1097/00002030-200409030-00006. [DOI] [PubMed] [Google Scholar]
  93. Staszewski S, Morale-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865–1873. doi: 10.1056/NEJM199912163412501. [DOI] [PubMed] [Google Scholar]
  94. Stellbrink HJ. Antiviral drugs in the treatment of AIDS: what is in the pipeline. Eur J Med Res. 2007;12:483–495. [PubMed] [Google Scholar]
  95. Sticht J, Humbert M, Findlow S, et al. A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol. 2005;12:671–677. doi: 10.1038/nsmb964. [DOI] [PubMed] [Google Scholar]
  96. Tang C, Loeliger E, Kinde I. Antiviral inhibition of the HIV-1 capsid protein. J Mol Biol. 2003;327:1013–1020. doi: 10.1016/S0022-2836(03)00289-4. [DOI] [PubMed] [Google Scholar]
  97. Temin HM. Viral oncogenes. Cold Spring Harb Symp Quant Biol. 1980;44 (Pt 1):1–7. [PubMed] [Google Scholar]
  98. Tengelsen LA, Pederson NE, Shaver PR, Wathen MW, Homa FL. Herpes simplex virus type 1 DNA cleavage and encapsidation require the product of the UL28 gene: isolation and characterization of two UL28 deletion mutants. J Virol. 1993;67:3470–3480. doi: 10.1128/jvi.67.6.3470-3480.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Torriani FJ, Freeman WR, Macdonald JC, Karavellas MP, Durand DM, Jeffrey DD. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS. 2000;14:173–180. doi: 10.1097/00002030-200001280-00013. [DOI] [PubMed] [Google Scholar]
  100. Townsend L, Devivar R, Turk S, Nassiri M, Drach J. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-d-ribofuranosyl)benzimidazoles. J Med Chem. 1995;38:4098–4105. doi: 10.1021/jm00020a025. [DOI] [PubMed] [Google Scholar]
  101. Turlure F, Devroe E, Silver PA, Engelman A. Human cell proteins and human immunodeficiency virus DNA integration. Front Biosci. 2004;9:3187–3208. doi: 10.2741/1472. [DOI] [PubMed] [Google Scholar]
  102. Umehara T, Fukuda K, Nishikawa F, Kohara M, Hasegawa T, Nishikawa S. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3. J Biochem. 2005;137:339–347. doi: 10.1093/jb/mvi042. [DOI] [PubMed] [Google Scholar]
  103. Underwood M, Harvey R, Stanat S, Hemphill M, Miller T, Drach J, Townsend L, Biron K. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol. 1998;72:717–725. doi: 10.1128/jvi.72.1.717-725.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Van Maele B, Debyser Z. HIV-1 integration: an interplay between HIV-1 integrase, cellular, and viral proteins. AIDS Rev. 2005;7:26–43. [PubMed] [Google Scholar]
  105. Wai JS, Egbertson MS, Payne LS, Fisher TE, Embrey MW, Tran LO, Melamed JY, Langford HM, Jr Guare JP, Zhuang L. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. J Med Chem. 2000;43:4923–4926. doi: 10.1021/jm000176b. [DOI] [PubMed] [Google Scholar]
  106. Wainberg MA. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2003;34:2–7. doi: 10.1097/00126334-200309011-00002. [DOI] [PubMed] [Google Scholar]
  107. Weber O, Schlemmer KH, Hartmann E, Hagelschuer I, Paessens A, Graef E, Deres K, Goldmann S, Niewoehner U, Stoltefuss J, Haebich D, Ruebsame-Waigmann H, Wohlfeil S. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. 2002;54:69–78. doi: 10.1016/S0166-3542(01)00216-9. [DOI] [PubMed] [Google Scholar]
  108. Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol. 1995;69:376–386. doi: 10.1128/jvi.69.1.376-386.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Witvrouw M, Fikkert V, Vercammen J, Van Maele B, Engelborghs Y, Debyser Z. Identification of authentic inhibitors of HIV-integration. Curr Med Chem Anti-Infective Agents. 2005;4:153–165. doi: 10.2174/1568012053507007. [DOI] [Google Scholar]
  110. Wolfe P, Hawley P, Boccia G, Clendeninn N, Paradiso L, Shaw T, Chi-Burris K (2001) Safety and efficacy of capravirine versus placebo in HIV-infected patients failing a NNRTI-containing regimen: results of a Phase II, double-blind, placebo-controlled study. In: 8th conference on retroviruses and opportunistic infections. Chicago, IL, Abstract 323
  111. Yu D, Weller SK. Herpes simplex virus type 1 cleavage and packaging proteins UL15 and UL28 are associated with B but not C capsids during packaging. J Virol. 1998;72:7428–7439. doi: 10.1128/jvi.72.9.7428-7439.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Yu D, Sheaffer AK, Tenney DJ, Weller SK. Characterization of ICP6:lacZ insertion mutants of the UL15 gene of herpes simplex virus type 1 reveals the translation of two proteins. J Virol. 1997;71:2656–2665. doi: 10.1128/jvi.71.4.2656-2665.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Zhou J, Yuan X, Dismuke D, et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol. 2004;78:922–929. doi: 10.1128/JVI.78.2.922-929.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Zhuang L, Wai JS, Embrey MW, Fisher TE, Egbertson MS, Payne LS, Guare JP, Jr, Vacca JP, Hazuda DJ, Felock PJ, Wolfe AL, Stillmock KA, Witmer MV, Moyer G, Schleif WA, Gabrye-ski LJ, Leonard YM, Lynch JJ, Jr, Michelson SR, Young SD. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem. 2003;46:453–456. doi: 10.1021/jm025553u. [DOI] [PubMed] [Google Scholar]

Articles from Antiviral Strategies are provided here courtesy of Nature Publishing Group

RESOURCES